Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Premenopausal Breast Cancer|Metastatic Breast Cancer|ER Positive Breast Cancer
Interventions: DRUG: Goserelin|DRUG: Fulvestrant|DRUG: Capivasertib|DRUG: Durvalumab
Sponsor: National Taiwan University Hospital